Endogenous retrovirus envelope protein gp70 (gp70)

The endogenous retrovirus envelope protein gp70 is the surface subunit (SU) of the envelope (Env) glycoprotein complex found in various endogenous retroviruses (ERVs), most notably the Murine Leukemia Virus (MuLV) and its human counterparts like HERV-K (NIH, 2024). In its functional form, gp70 is responsible for binding to specific cellular receptors to facilitate viral entry and membrane fusion (PubMed, 1984). While ERVs are typically silenced in healthy tissues through epigenetic mechanisms, gp70 is frequently reactivated and overexpressed in a wide range of cancers, including colorectal carcinoma and melanoma, where it serves as a potent tumor-associated antigen (TAA) (NIH, 2021). In murine models of systemic lupus erythematosus (SLE), gp70 is a major autoantigen that forms pathogenic immune complexes with anti-gp70 antibodies, leading to glomerulonephritis and systemic inflammation (NIH, 2019). Therapeutically, gp70 and its human equivalents are being explored as targets for chimeric antigen receptor (CAR) T-cell therapies, vaccines, and monoclonal antibodies (AACR, 2024). For instance, the monoclonal antibody temelimab targets the related HERV-W envelope protein to treat neurodegenerative diseases like multiple sclerosis (GeNeuro, 2024).

Other names

Env gp70Surface subunit of EnvSU subunitMuLV gp70HERV-K surface subunitRetroviral gp70MelARV Env gp70

Immunotherapy targeting tumor-associated antigens to induce cell death; neutralization of pathogenic viral proteins or immune complexes to reduce inflammation.